FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the period from January 1, 2003
to November 17, 2003
Lorus Therapeutics Inc.
-----------------------
(Translation of registrant's name into English)
2 Meridian Road, Toronto, Ontario M9W 4Z7
-----------------------------------------
(Address of principal executive offices)
[Indicate by check mark whether the
registrant files or will file annual reports
under cover Form 20-F or Form 40-F.]
Form 20-F ___ ____ Form 40-F __ X__
[Indicate by check mark whether the registrant by
furnishing the information contained in this Form is also
thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under
the Securities Exchange Act of 1934.
Yes ________ No ____X___
[If "Yes" is marked, indicate below the file number
assigned to the registrant in connection with Rule 12g3-2(b): 82- _____
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
Lorus Therapeutics Inc.
Date: November 19, 2003 By: "Shane Ellis"
----------------- ----------------
Shane Ellis
Vice President,Legal Affairs
Corporate Secretary
Index for the 6-K filing
99.1 Press release: Appointment of Robert Capizzi to Lorus Board
99.2 Press release: Various staff change announcement
99.3 Press release: Lorus presents research findings at ONCOGENE meeting
99.4 Press release: US NCI clinical development for GTI-2040
99.5 Press release: Lorus allowed Mexico patent to protect Virulizin
99.6 Press release: Lorus presents Virulizin at InCan meeting in Mexico
99.7 Press release: FDA grants Orphan drug Status to GTI-2040 on Renal Cell
Carcinoma
99.8 Press release: Q203 results announcement
99.9 Press release: Lorus to advance GTI-2501 into phase II
99.10 Press release: Lorus publishes results of Virulizin in peer reviewed
journal
99.11 Press release: Lorus announces US patent allowance on Virulizin
99.12 Press release: Lorus allowed Canadian patent on Antimicrobial drugs
99.13 Press release: Q303 results announcement
99.14 Press release: Lorus announces progress with phase III Virulizin trial
99.15 Press release: Lorus announces scientific publication that expand the
application of Virulizin
99.16 Press release: Lorus publishes results of GTI-2040 against broad range
indications
99.17 Press release: Lorus announces Virulizin presentation at Lustgarden
conference
99.18 Press release: Lorus reports year end results of fiscal 2003
99.19 Press release: Lorus announces the initiation of the 3rd clinical trial
with US NCI
99.20 Press release: Lorus announces presenting at a Gene Therapy conference
99.21 Press release: Lorus announces presenting at the Biopartnering in
Europe
99.22 Press release: Lorus announces the publication of Virulizin mechanism
of Action Study
99.23 Press release: Lorus sponsors Lung Cancer meeting
99.24 Press release: Lorus closes financing
99.25 Press release: Lorus files final prospectus
99.26 Press release: Lorus files preliminary short-form prospectus
99.27 Press release: Lorus allowed US Thiodoxin Reductase patent
99.28 Press release: Lorus allowed US patent on antisense anticancer target
99.29 Press release: Lorus allowed US Antimicrobiology patent
99.30 Press release: Expansion of a phase II clinical trial with Renal Cell
Carcinoma
99.31 Press release: Lorus announces Virulizin Europe patent
99.32 Press release: Lorus announces the start of Leukemia clinical trial
with GTI-2040 with NCI
99.33 Press release: Lorus allowed Canadian U-Sense patent
99.34 Press release; Lorus announces the starts of breast cancer study with
GTI-2040 with NCI
99.35 Press release: Lorus announces a patent allowance for its subsidiary
Nuchem
99.36 Press release: Lorus announces global expansion of Virulizin phase III
trial
99.37 Press release: Lorus publishes results on Genetherapy
99.38 Press release: Lorus to present at BioContact 2003
99.39 Press release: Lorus to present results of GTI-2040 at AACR meeting
99.40 Press release: Lorus Supports PanCan awareness month
99.41 Press release: Lorus presents at Bio-Europe 2003 in Germany
99.42 Press release: Lorus announces Q1 04 results
99.43 Press release: Lorus participates in 39th ASCO meeting